Skip to main content
Premium Trial:

Request an Annual Quote

Pyrosequencing Sells DNA Analysis System to Harvard Cancer Center

NEW YORK, Nov. 21, 2000 – Pyrosequencing of Uppsala, Sweden announced Tuesday it had sold its PSQ 96 DNA sequencing system to the Harvard Center for Cancer Prevention.

Harvard will use the system, which sells for $89,000 , to analyze genetic variations in sample populations and compare this information with known risk factors for colon cancer, breast cancer, and other diseases.

The PSQ 96 operates on a proprietary    “sequencing-by-synthesis” technology, which uses a luciferase light-generating reaction to map sequences in minutes. Researchers can use it for rapid SNP analysis Tag sequencing.

" We are delighted that Harvard Center for Cancer Prevention has chosen our PSQ 96 System to advance their research in cancer and other important diseases," said Pyrosequencing CEO Erik Wallden. " Our instruments and reagents continue to gain broad acceptance among the world's leading academic institutions and we believe that our approach will be the new standard in applied genetic analysis."

Pyrosequencing has also sold its PSQ 96 to Sweden's Karolinska Institute, the National Institutes of Health, the National Cancer Center of Tokyo, and the University of California at Davis.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.